Kate O’Neill

Community Spotlight Research News

Understanding key differences among Alzheimer’s clinical trials in Down syndrome

LuMind IDSC releases guide for families learning about Alzheimer's disease therapies MARCH 14, 2025 -…

Kate O’NeillMarch 13, 2025

Research News Community Spotlight Press Release Research Spotlight

RAND report shows benefit of investment in future health outcomes for adults with Down syndrome

10/1/2024 | For immediate release | Contact: Kate O'Neill ([email protected]) Investment in Alzheimer’s Research Today…

Kate O’NeillSeptember 18, 2024

Research News Research Spotlight

Updates from AAIC: Down syndrome community boosted by FDA confirmation of label and new anti-amyloid clinical trial

Information revealed at the 2024 AAIC conference on the ACTC-DS-led study in DS-associated Alzheimer's disease…

Kate O’NeillAugust 2, 2024

Community Spotlight Press Release Research News

FDA issues approval for new Alzheimer’s drug Kisunla; Down syndrome community is optimistic

FDA issues approval for Kisunla, new Alzheimer's drug; Down syndrome community optimistic On Tuesday, July…

Kate O’NeillJuly 3, 2024

Alzheimer's disease in people with Down syndrome

Community Spotlight Press Release Research News Research Spotlight

Down syndrome population will see a clinical trial of new Alzheimer’s drug

Major pharmaceutical company announces Down syndrome population will see a clinical trial of new Alzheimer’s…

Kate O’NeillJune 11, 2024

Community Spotlight Publications Research News Research Spotlight

Down syndrome collaborators now published in Alzheimer’s and Dementia

“Adapting prescribing criteria for amyloid‐targeted antibodies for adults with Down syndrome” published in the journal…

Kate O’NeillMarch 15, 2024

Feb2018 AlzheimersInDs 637297080437914151 o6UI7E

Research News Community Spotlight Research Spotlight

LuMind IDSC statement on FDA Advisory Committee for promising Alzheimer’s drug, donanemab

LuMind IDSC is encouraged by today’s news that the U.S. Food and Drug Administration (FDA)…

Kate O’NeillMarch 8, 2024

Community Spotlight Research Spotlight

Message from the CEO: a look ahead to 2024

“I want to enjoy my life for a long time. I want to grow old…

Kate O’NeillJanuary 18, 2024

Community Spotlight

Progress in 2023 – our annual impact report

Thanks to the extraordinary support and engagement of the Down syndrome community, LuMind IDSC is…

Kate O’NeillDecember 21, 2023

Community Spotlight

LuMind IDSC names new Director of Community Programs

Following a five-month, national search, LuMind IDSC Down Syndrome Foundation announced the appointment of Christina…

Kate O’NeillSeptember 21, 2023